Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by LaserStock29on Apr 02, 2020 8:37am
198 Views
Post# 30871208

RE:RE:RE:RE:RE:I was invested here until I took an arrow to the knee...

RE:RE:RE:RE:RE:I was invested here until I took an arrow to the knee...Alot if not all safety can be determined by the initial 7 to 14 day checks.. the 1 month xray can do imaging.. of course the 3 month u get to see redness etc. All u want to hear is that the side effects of 2nd treatment were at grade 1 or 2. Nothing serious....... It's kind of difficult to injure the muscle layer of the bladder wall when your using green light which doesn't penetrate that deep and have full controls on refracted light w a diameter....... But let's all act like the markets dont know that. Cant say the risk is any better that one in a million shot ... it's all up in the air....... Gimme a break if the first 2 are safe again we should gap up to .60 and start running erasing the agm crash of 2019
skier59 wrote: That's your opinion gojo, so unless you have been told it specifically, let's wait and see what the second quarterly report tells us when it gets released probably next week. I'm thinking we will get atleast some clues, if not facts, as to what is going on with the study.


gojotv! wrote: As I've said before, don't expect 3 and 6 month data in this phase of testing as we had with Phase 1.
Phase one was about measuring toxicity, so results could be shared early, but in this phase efficacy is the investigative goal... and the treatment modality is to give each patient two treatments six months apart. I got this from Dr. Sherri MacFarland herself.
So it's estrememly doubtful that results will be shared before patients are in the 9months-to-1year post treatment phase.
Please stop making me repeat this by posting false speculation - you're making me sound like a basher.
GLTA longs!



enriquesuave wrote: 10 patients treated us awesome as 3 and 6 months data can and may be presented in mid- May at the AUA meeting 3 months from now. Don't know what the plan is but if data is there, we will be on a one way track up from there. IMO 






Bullboard Posts